NewcelX Ltd.

NewcelX Ltd. is a biopharmaceutical company focused on developing stem-cell-derived therapies for diabetes. Its pipeline includes NCEL-101, a cellular therapy based on enriched pancreatic islet-like clusters for Type 1 diabetes and Type 2 insulin-dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy for amyotrophic lateral sclerosis and neurodegenerative indications; and DOXA, a small-molecule platform for sleep disorders, neurodegenerative/neuroinflammatory diseases, and diabetes-associated neurological disorders. The company also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. Founded in 2008, NewcelX is headquartered in Kloten, Switzerland.